Volume 11, Number 1—January 2005
Research
Anti–SARS-CoV Immunoglobulin G in Healthcare Workers, Guangzhou, China
Wei-Qing Chen*
, Ci-Yong Lu*, Tze-wai Wong†, Wen-Hua Ling*, Zhong-Ning Lin*, Yuan-Tao Hao*, Qing Liu*, Ji-Qian Fang*, Yun He*, Fu-Tian Luo*, Jin Jing*, Li Ling*, Xiang Ma*, Yi-Min Liu*, Gui-Hua Chen*, Jian Huang*, Yuan-Sen Jiang*, Wen-Qi Jiang*, He-Qun Zou*, and Guang-Mei Yan*
, Ci-Yong Lu*, Tze-wai Wong†, Wen-Hua Ling*, Zhong-Ning Lin*, Yuan-Tao Hao*, Qing Liu*, Ji-Qian Fang*, Yun He*, Fu-Tian Luo*, Jin Jing*, Li Ling*, Xiang Ma*, Yi-Min Liu*, Gui-Hua Chen*, Jian Huang*, Yuan-Sen Jiang*, Wen-Qi Jiang*, He-Qun Zou*, and Guang-Mei Yan*
Table 3
Severe acute respiratory (SARS) immunoglobulin G prevalence among healthcare workers with and without SARS in 5 affiliated hospitals
| Affiliated hospital | Healthcare workers with SARS |
Healthcare workers without SARS |
||
|---|---|---|---|---|
| No. participants | No. positive (%) | No. participants | No. positive (%) | |
| First | 0 | 0 | 389 | 4 (1) |
| Second | 73 | 63 (86.3) | 288 | 8 (2.8) |
| Third | 17 | 17 (100) | 380 | 3 (0.8) |
| Cancer | 0 | 0 | 371 | 2 (0.5) |
| Fifth | 0 | 0 | 338 | 1 (0.3) |
| Total/overall percentage | 90 | 80 (88.9) | 1,766 | 18 (1) |
Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.